| Abstract P222 – Table 1. Proportion of patients with HIV RNA <50 copies/mL (observed case) by analysis time point in the extension phase of AMBER and EMERALD, ITT. | ||||
|---|---|---|---|---|
| AMBER | AMBER | EMERALD | EMERALD | |
| D/C/F/TAF | Control | D/C/F/TAF | Control | |
| Analysis set: Intent‐to‐treat, N | 311 | 310 | 699 | 337 |
| Week 96 + 6 months (N) | 303 | 296 | 688 | 334 |
| <50 copies/mL, n (%) | 296 (97.7) | 285 (96.3) | 673 (97.8) | 327 (97.9) |
| Week 96 + 12 months (N) | 194 | 214 | 611 | 302 |
| <50 copies/mL, n (%) | 192 (99.0) | 207 (96.7) | 601 (98.4) | 294 (97.4) |
| Week 96 + 18 months (N) | 158 | 167 | 461 | 225 |
| <50 copies/mL, n (%) | 155 (98.1) | 164 (98.2) | 459 (99.6) | 222 (98.7) |
| Week 96 + 24 months (N) | 81 | 92 | 280 | 134 |
| <50 copies/mL, n (%) | 79 (97.5) | 88 (95.7) | 278 (99.3) | 132 (98.5) |
| Week 96 + 30 months (N) | 57 | 58 | 135 | 64 |
| <50 copies/mL, n (%) | 54 (94.7) | 53 (91.4) | 134 (99.3) | 64 (100) |
| Week 96 + 36 months (N) | 19 | 16a | 52 | 26 |
| <50 copies/mL, n (%) | 19 (100.0) | 11 (68.8) | 51 (98.1) | 26 (100) |
| Week 96 + 42 months (N) | NA | NA | 16 | 7 |
| <50 copies/mL, n (%) | NA | NA | 16 (100) | 7 (100) |
aOf the 5 patients with HIV RNA ≥50 copies/mL, 3 had HIV RNA <200 copies/mL.